Glufosfamide
Phase 3Small molecule
Glufosfamide is one of 179 small molecule programs targeting Small Cell Lung Carcinoma. It is currently in Phase 3.
6
Indications
9
Total Trials
1
Active Trials
178
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Glufosfamide
TThreshold Pharmaceuticals
Phase 3
Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Lenvima
EisaiPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer3 trials
Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00005053·35 enrolled
Glioblastoma Multiforme1 trial
Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00014300·32 enrolled
Small Cell Lung Carcinoma1 trial
Non-Small Cell Lung Cancer1 trial
Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00005055·39 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glufosfamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TThreshold Pharmaceuticals